Literature DB >> 8791258

Respiratory infections: community-acquired pneumonia and newer microbes.

H Y Reynolds1.   

Abstract

Respiratory infections, especially community-acquired forms of pneumonia (CAP), are challenging for clinicians because (1) a causative microorganism can only be found in about 50% of cases; (2) initial therapy, therefore, must be based on a probable or most likely etiology in the context of the patient's overall medical condition; and (3) new microbes or those considered previously as normal flora or less virulent forms seem responsible for some cases. It is important to be acquainted with new causes of infection which include Legionella species, Chlamydia pneumoniae, diphtheroids in certain instances (Corynebacterium pseudodiphtheriticum), and viruses such as the Hanta strains. Infections with Bordetella pertussis are increasing. However, the ever present and most common cause of CAP, Streptococcus pneumoniae, continues to present problems because of increasing antibiotic resistance, the high case fatality rate when bacteremia accompanies pneumonia, and the inability to give prophylactic immunization to all people with risk factors for this infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8791258      PMCID: PMC7102149          DOI: 10.1007/bf00173136

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  85 in total

1.  IgG antibody reactive with five serotypes of Streptococcus pneumoniae in commercial intravenous immunoglobulin preparations.

Authors:  R J Hamill; D M Musher; J E Groover; P J Zavell; D A Watson
Journal:  J Infect Dis       Date:  1992-07       Impact factor: 5.226

Review 2.  Antimicrobial resistance in Streptococcus pneumoniae: can immunization prevent its spread?

Authors:  R S Munford; T V Murphy
Journal:  J Investig Med       Date:  1994-12       Impact factor: 2.895

Review 3.  Pathogenesis of pneumococcal infection.

Authors:  E I Tuomanen; R Austrian; H R Masure
Journal:  N Engl J Med       Date:  1995-05-11       Impact factor: 91.245

Review 4.  Molecular pathology--diagnosis of infectious disease.

Authors:  S P Naber
Journal:  N Engl J Med       Date:  1994-11-03       Impact factor: 91.245

5.  Community-acquired pneumonia: impact of immune status.

Authors:  L M Mundy; P G Auwaerter; D Oldach; M L Warner; A Burton; E Vance; C A Gaydos; J M Joseph; R Gopalan; R D Moore
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

6.  Bacteremic hemophilus influenzae pneumonia in adults. A report of 24 cases and a review of the literature.

Authors:  D C Levin; M I Schwarz; R A Matthay; F M LaForce
Journal:  Am J Med       Date:  1977-02       Impact factor: 4.965

7.  Pneumococcal vaccine recommendation. American College of Physicians; Philadelphia, Pennsylvania Endorsed by the advisory committee on immunization practices, council of medical societies.

Authors: 
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

8.  The effects of inhaled interferon gamma in normal human airways.

Authors:  R J Martin; M Boguniewicz; J E Henson; A C Celniker; M Williams; R C Giorno; D Y Leung
Journal:  Am Rev Respir Dis       Date:  1993-12

Review 9.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

10.  Danger of sputum purulence screens in culture of Legionella species.

Authors:  J G Ingram; J F Plouffe
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

View more
  2 in total

1.  Clinical evaluation methods for new antimicrobial agents to treat respiratory infections: Report of the Committee for the Respiratory System, Japan Society of Chemotherapy.

Authors:  A. Saito; Fumio Miki; Kotaro Oizumi; Naoto Rikitomi; Akira Watanabe; Hironobu Koga; Yoshito Niki; Nobuchika Kusano
Journal:  J Infect Chemother       Date:  1999-06       Impact factor: 2.211

Review 2.  Optimal pharmacological therapy for community-acquired pneumonia: the role of dual antibacterial therapy.

Authors:  Benjamin J Epstein; John G Gums
Journal:  Drugs       Date:  2005       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.